Nodular thyroid disease other imaging findings

Nodular thyroid disease Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Nodular thyroid disease from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Ultrasound
Fine Needle Aspiration
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Nodular thyroid disease other imaging findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Nodular thyroid disease other imaging findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Nodular thyroid disease other imaging findings
CDC on Nodular thyroid disease other imaging findings
Nodular thyroid disease other imaging findings in the news
Blogs on Nodular thyroid disease other imaging findings
Directions to Hospitals Treating Nodular thyroid disease
Risk calculators and risk factors for Nodular thyroid disease other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Scintigraphy

• Radionucleotide scanning is most helpful in the work-up of indeterminate FNAs. Hot nodules are almost always benign, whereas warm or cold nodules should likely be removed.

  • Alternatively, a ‘suppression scan’ can be obtained. Thyroxine is given in a dose sufficient to suppress TSH secretion and a second scan is done. Uptake will be low or undetectable in nonautonomous tissue (bad), but persist in autonomous tissue (good). If the uptake corresponds to the palpable nodule, it can be presumed benign and the patient can be followed.